Potential five-year life years associated with stage IV reductions in NHS Galleri Trial

BackgroundNHS-Galleri did not reach its prespecified primary endpoint of a reduction in combined stage III and IV cases, but reported fewer stage IV cancers after annual multi-cancer early detection screening. We estimated the potential five-year life-years associated with the cancer-specific stage IV differences observed during the two incident screening rounds. MethodsWe used intervention and control stage IV counts for ten prespecified cancers reported in the NHS-Galleri ASCO 2026 presentation. For each cancer, the randomized-arm count difference was multiplied by the difference in five-year restricted mean survival time between stage III and IV, estimated from England stage-specific five-year net survival using a constant-hazard fit. Adverse cancer-specific differences remained in the model. Results were annualized across the two incident rounds and scaled per million people screened. Sampling intervals used an independent Poisson approximation for arm-specific counts. FindingsAcross the ten evaluable cancers, the intervention and control arms had 180 and 239 stage IV diagnoses during the incident rounds. The conditional projection was 66.3 potential life-years over five years in the trial intervention cohort, equivalent to 466 per million people screened annually (95% sampling interval 190-743). For a population of 10 million, the corresponding projection was 4,664 annually (1,896-7,432). Colorectal, lung, and esophageal cancers accounted for 79% of the net projection. Pancreatic, ovarian, and lymphoid cancers contributed negatively because their observed stage IV counts favored control. InterpretationIf the observed incident-round reduction in stage IV diagnoses represents true downstaging to stage III, it could produce meaningful population health gains. This conditional estimate is not evidence of mortality reduction. Longer follow-up remains necessary to distinguish benefit from chance, lead-time and length biases, overdiagnosis, and differences in tumor biology.